SNOA
Sonoma Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.33
+0.38%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 21.9M | 19.5M | 14.3M | 12.7M | 13.3M |
| Cost of Revenue | 13.4M | 12.1M | 8.8M | 8.0M | 8.8M |
| Gross Profit | 8.5M | 7.4M | 5.5M | 4.7M | 4.5M |
| Operating Expenses | |||||
| R&D Expense | 2.3M | 2.3M | 1.8M | 1.9M | 207.0K |
| SG&A Expense | 7.7M | 7.6M | 7.4M | 7.6M | 8.8M |
| General & Admin Expense | — | — | 7.2M | — | — |
| Selling & Marketing Expense | — | — | 190.0K | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 9.9M | 9.9M | 9.2M | 9.4M | 9.0M |
| Cost and Expenses | 23.3M | 22.0M | 18.0M | 17.4M | 17.8M |
| Operating Income (EBIT) | (1.4M) | (2.5M) | (3.7M) | (4.7M) | (4.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 16.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | 16.0K |
| Other Non-Op Income/Expense | (1.1M) | (958.0K) | 803.0K | (330.0K) | (614.0K) |
| Non-Operating Income (excl Interest) | 290.0K | — | (803.0K) | 330.0K | 614.0K |
| EBT (Pre-Tax Income) | (2.5M) | (3.4M) | (2.9M) | (5.0M) | (5.2M) |
| Income Tax Expense | (243.0K) | (244.0K) | 550.0K | (196.0K) | (33.0K) |
| Bottom Line | |||||
| Net Income | (2.3M) | (3.2M) | (3.5M) | (4.8M) | (5.2M) |
| Earnings from Cont. Ops | (2.3M) | (3.2M) | (3.5M) | (4.8M) | (5.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.3M) | (3.2M) | (3.5M) | (4.8M) | (5.2M) |
| Per Share | |||||
| Basic EPS | ($1.22) | ($1.89) | ($2.79) | ($5.32) | ($15.18) |
| Diluted EPS | ($1.22) | ($1.89) | ($2.79) | ($5.32) | ($15.18) |
| Revenue Per Share | $5.70 | $11.60 | $11.51 | $14.01 | $39.10 |
| Shares | |||||
| Basic Shares Outstanding | 3.8M | 1.7M | 1.2M | 909000 | 339400 |
| Diluted Shares Outstanding | 3.8M | 1.7M | 1.2M | 909000 | 339400 |
| Profitability Metrics | |||||
| EBITDA | (1.6M) | (2.3M) | (2.8M) | (4.9M) | (5.1M) |
| D&A | 103.0K | 139.0K | 138.0K | 176.0K | 125.0K |
| EBIT | (1.7M) | (2.5M) | (2.9M) | (5.0M) | (5.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026